以黄芪为君药中药复方治疗糖尿病肾病有效性及安全性Meta分析

发布时间：2018-05-25 10:21

本文选题：黄芪 + 中药复方　；参考：《辽宁中医药大学》2017年硕士论文

【摘要】：目的:系统评价以黄芪为君药中药复方治疗糖尿病肾病的有效性及安全性。方法:根据Cochrane协作网系统评价方法,计算机检索Pub Med、中国知网、万方数据库,同时手工检索杂志刊登的相关文献,全面收集2016年12月之前收录的以黄芪为君药中药复方治疗糖尿病肾病的随机对照试验。采取改良的Jadad量表评价文献质量,应用Rev Man5.3软件进行Meta分析,分析指标为二分类资料,用比值比(OR)及其95%可信区间(95%CI)表示;分析指标为连续型资料,用加权均数差(MD)及其95%可信区间(95%CI)表示。结果:1.共纳入15个改良的Jadad量表评分3分以上的随机对照试验,共计1156例糖尿病肾病患者。2.有效性方面:(1)以黄芪为君药中药复方在治疗糖尿病肾病与对照组比较合并效应量OR=3.51,95%CI=(2.48,4.95),P0.00001。(2)以黄芪为君药中药复方在降低糖尿病肾病患者空腹血糖方面与对照组比较合并效应量MD=-0.61,95%CI=(-0.93,-0.28),P=0.0002。(3)以黄芪为君药中药复方在降低糖尿病肾病患者餐后2小时血糖方面与对照组比较合并效应量示MD=-0.85,95%CI=(-1.18,-0.51),P0.00001。(4)以黄芪为君药中药复方在降低糖尿病肾病患者尿白蛋白方面与对照组比较合并效应量示MD=-25.38,95%CI=(-32.74,-18.01),P0.00001。(5)以黄芪为君药中药复方在降低糖尿病肾病患者24小时尿蛋白定量方面与对照组比较合并效应量示MD=-0.37,95%CI=(-0.51,-0.24),P0.00001。3.安全性方面:认为以黄芪为君药中药复方治疗糖尿病肾病无严重不良反应。结论:以黄芪为君药中药复方是相对安全和有效治疗糖尿病肾病的药物。
[Abstract]:Objective: to evaluate the efficacy and safety of Astragalus membranaceus for diabetic nephropathy. Methods: according to the evaluation method of Cochrane cooperative network system, Pub Med, China Zhiwang, Wanfang database were searched by computer, and the related literatures published in the journal were also searched manually. A randomized controlled trial on the treatment of diabetic nephropathy with astragalus membranaceus as monomial compound was collected before December 2016. The improved Jadad scale was used to evaluate the quality of the literature, and the Meta analysis was carried out by Rev Man5.3 software. The analysis index was classified data, expressed by ratio (OR) and 95% confidence interval (95 CI), and the analysis index was continuous data. The weighted mean difference (MD) and its 95% confidence interval (CI) are used. The result is 1: 1. A total of 1156 diabetic nephropathy patients were enrolled in 15 randomized controlled trials with improved Jadad scores above 3. Effectiveness: 1) Astragalus as the monarch medicine Chinese compound in the treatment of diabetic nephropathy compared with the control group in comparison with the combined effect of the dose of ORX 3.51C95 CIHU 2.48-4.95C P0.00001. 2) Astragalus as the monarch herbal compound in reducing fasting blood glucose in patients with diabetic nephropathy, compared with the control group, the combination of Astragalus membranaceus as the monarch medicine in the treatment of diabetic nephropathy patients compared with the control group (Astragalus membranaceus as your medicine compound of traditional Chinese medicine in reducing 2 hours postprandial blood glucose in diabetic nephropathy patients compared with the control group, the combined effect of MD-0.85 ~ 95CIK-1.18C1-0.51P0.00001.44) Astragalus as your medicine compound can reduce urinary albumin in patients with diabetic nephropathy. Compared with the control group, the combined effect of MD-25.38 / 9595 showed that the combined effect of Astragalus membranaceus as a Chinese medicine in reducing the quantity of 24 hour urine protein in diabetic nephropathy patients was higher than that in the control group. The combined effect quantity showed that the combined effect of MD-0.37-95 and CI-0.31- 0.241- 0.241- 0.241- 0.24kg-P0.00001.3in reducing the quantity of urinary protein in patients with diabetic nephropathy was compared with that in the control group (P 0.00001. 5) and compared with that in the control group. Safety: Astragalus membranaceus as the monarch medicine compound treatment of diabetic nephropathy without serious adverse reactions. Conclusion: astragalus is a safe and effective drug for diabetic nephropathy.
【学位授予单位】：辽宁中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R259

【参考文献】